Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18823274 | PHARMACEUTICAL COMPOSITION | September 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18823257 | PHARMACEUTICAL COMPOSITION | September 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18739646 | Safe Flavoring Composition to Improve Compliance in Colon Cleansing Compositions | June 2024 | March 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18663349 | LISINOPRIL FORMULATIONS | May 2024 | October 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18517529 | PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY | November 2023 | October 2024 | Allow | 11 | 1 | 0 | No | No |
| 18496417 | Altering Net Charge on Mannosylated Dextrans to Maximize Target Tissue Uptake and Off Target Competitive Blocking | October 2023 | July 2024 | Allow | 8 | 1 | 0 | No | No |
| 18381775 | COMPOSITIONS FOR ANTIHYPERTENSIVE DRUGS | October 2023 | February 2025 | Abandon | 16 | 3 | 1 | Yes | No |
| 18484334 | PHARMACEUTICAL COMPOSITION | October 2023 | November 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18450553 | LISINOPRIL FORMULATIONS | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18233560 | EMULSIONS FOR TREATING MUCOUS MEMBRANE INFECTIONS | August 2023 | April 2025 | Allow | 20 | 1 | 1 | No | No |
| 18356331 | CATHETER LOCK SOLUTION COMPRISING SODIUM CITRATE AND BENZYL ALCOHOL | July 2023 | December 2024 | Allow | 17 | 1 | 1 | No | No |
| 18357004 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | July 2023 | March 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18222690 | BI-FUNCTIONAL CO-POLYMER USE FOR OPHTHALMIC AND OTHER TOPICAL AND LOCAL APPLICATIONS | July 2023 | December 2024 | Allow | 17 | 1 | 0 | No | No |
| 18331093 | COMPOSITIONS, FORMULATIONS AND INTERLEUKIN PRODUCTION AND PURIFICATION | June 2023 | March 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18299444 | METHODS OF ALLEVIATING SYMPTOMS OF OCULAR SURFACE DISCOMFORT USING MEDICAL ICE SLURRY | April 2023 | November 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18187165 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES | March 2023 | May 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18171007 | TASTE-MASKING ORAL FORMULATIONS OF FASUDIL | February 2023 | November 2024 | Abandon | 21 | 3 | 0 | No | No |
| 18020544 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND AN ACTIVE AGENT | February 2023 | August 2024 | Allow | 18 | 0 | 1 | No | No |
| 18082826 | Base Composition for Tape Agent | December 2022 | March 2025 | Abandon | 27 | 2 | 0 | No | No |
| 17992348 | FORMULATIONS/COMPOSITIONS COMPRISING A BTK INHIBITOR | November 2022 | June 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17932736 | BIOMIMETIC VESICLES AND USES THEREOF | September 2022 | July 2024 | Allow | 22 | 0 | 1 | No | No |
| 17930373 | METHODS FOR DELIVERING AGENTS WITH PRE-FILLED SYRINGES TO MINIMIZE INTRAOCULAR INFLAMMATION | September 2022 | May 2025 | Allow | 33 | 4 | 0 | Yes | No |
| 17901108 | COMBINATION OF POLYETHYLENE GLYCOL AND RAPAMYCIN AND USE THEREOF | September 2022 | April 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17898223 | COMPOSITIONS AND METHODS FOR INVASIVE AND NON-INVASIVE PROCEDURAL SKINCARE | August 2022 | July 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17896280 | LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES | August 2022 | November 2024 | Allow | 27 | 1 | 1 | No | No |
| 17664105 | SELF-EMULSIFYING FORMULATIONS OF DIM-RELATED INDOLES | May 2022 | January 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17733210 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | April 2022 | December 2024 | Abandon | 32 | 4 | 0 | Yes | Yes |
| 17728382 | Metal Aluminum Nano-Adjuvant, Vaccine Composition And Preparation Method Therefor And Use Thereof | April 2022 | July 2024 | Allow | 27 | 1 | 1 | No | No |
| 17653172 | BIODEGRADABLE NON-WOVEN FABRIC SHEET | March 2022 | January 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17668356 | STORAGE STABLE SOLUTION COMPRISING HYPOCHLOROUS ACID AND/OR HYPOCHLORITE | February 2022 | November 2024 | Abandon | 33 | 2 | 0 | No | No |
| 17570548 | METHOD OF MANUFACTURING AN ORALLY DISINTIGRATING TABLET | January 2022 | May 2025 | Abandon | 40 | 3 | 1 | No | No |
| 17604691 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY ARRHYTHMIAS | October 2021 | January 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17601409 | INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL | October 2021 | January 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17488610 | ORAL SOLUBLE FILM CONTAINING SILDENAFIL CITRATE | September 2021 | May 2025 | Abandon | 43 | 5 | 1 | No | Yes |
| 17437279 | PARTICLES WITH BIOCIDAL COATING | September 2021 | March 2025 | Allow | 42 | 1 | 1 | No | No |
| 17393745 | BIODEGRADABLE SHEET WITH ANTIVIRAL PROPERTIES, MANUFACTURING METHOD THEREOF, AND USE THEREOF | August 2021 | April 2025 | Abandon | 44 | 2 | 1 | No | No |
| 17387329 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF HUPERZINE AND METHODS OF USING THE SAME | July 2021 | January 2025 | Allow | 42 | 4 | 1 | No | Yes |
| 17322815 | Anti-Viral Lactoferrin Facemask | May 2021 | November 2024 | Abandon | 42 | 2 | 1 | Yes | No |
| 17289185 | BIS(TRIETHOXYSILYLPROPYL)AMINES COMBINED WITH POYSACCHARIDES FOR CARING FOR AND SHAPING KERATINE FIBRES | April 2021 | February 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17232336 | HYDROGEL PARTICLE CARRIERS FOR DELIVERY OF THERAPEUTIC/DIAGNOSTIC AGENTS | April 2021 | November 2024 | Abandon | 43 | 3 | 1 | No | No |
| 17227978 | ORAL CARE COMPOSITIONS AND METHODS | April 2021 | November 2024 | Abandon | 43 | 7 | 1 | Yes | Yes |
| 17266382 | ARTIFICIAL BONE AND MANUFACTURING METHOD OF ARTIFICIAL BONE | February 2021 | August 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17260073 | VE-PTP INHIBITION IN GLAUCOMA | January 2021 | March 2025 | Abandon | 50 | 2 | 1 | No | Yes |
| 17255200 | PROCESSING METHOD FOR DRUG SUBSTANCE PARTICLES OF NON-UNIFORM PARTICLE SIZE | December 2020 | December 2024 | Abandon | 48 | 4 | 1 | Yes | No |
| 16973008 | COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF | December 2020 | May 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17100495 | JAPANESE ENCEPHALITIS VACCINE-CONTAINING MICRONEEDLE ARRAY | November 2020 | January 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17052694 | COMBINATION OF EXTRACTS OF QUINQUINA AND OF LEONTOPODIUM ALPINUM AND OF THE MANGANESE SALT OF L-PYRROLIDONE CARBOXYLIC ACID IN THE TREATMENT OF ALOPECIA | November 2020 | October 2024 | Abandon | 48 | 2 | 1 | No | No |
| 17083386 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | October 2020 | December 2024 | Abandon | 49 | 4 | 1 | Yes | Yes |
| 16964198 | COMPOSITE SCAFFOLD MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | October 2020 | November 2024 | Abandon | 52 | 2 | 1 | No | No |
| 17031841 | NANO EMULSION PROCESS FOR SCENTED LIQUIDS | September 2020 | February 2025 | Abandon | 53 | 2 | 1 | No | No |
| 15733458 | PROTECTING A BIOACTIVE AND/OR PRECURSOR THEREOF | July 2020 | June 2023 | Abandon | 35 | 5 | 1 | No | No |
| 16608740 | ENCAPSULATED NUTRITIONAL AND PHARMACEUTICAL COMPOSITIONS | October 2019 | May 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16236345 | COMPOSITIONS, DEVICES AND METHODS FOR PLANT HEALTH AND PEST CONTROL USING VAPOR ACTIVITY | December 2018 | February 2022 | Abandon | 37 | 9 | 0 | Yes | No |
| 16198793 | Topical Compositions, Process of Manufacture and Method of Use | November 2018 | February 2022 | Abandon | 39 | 5 | 1 | Yes | Yes |
| 16132857 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCES | September 2018 | February 2020 | Allow | 17 | 1 | 0 | No | No |
| 16055976 | OPHTHALMIC CONTACT LENS SOLUTIONS CONTAINING FORMS OF VITAMIN B | August 2018 | November 2019 | Allow | 15 | 1 | 0 | No | No |
| 15851550 | COMPOSITIONS, DEVICES AND METHODS FOR CONTROL OF PESTS USING VAPOR ACTIVITY | December 2017 | February 2020 | Abandon | 26 | 9 | 0 | No | No |
| 15571552 | Agrochemical Emulsions | November 2017 | December 2024 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 15714633 | INTRACAMERAL DRUG DELIVERY DEPOTS | September 2017 | August 2024 | Allow | 60 | 10 | 1 | Yes | Yes |
| 15412496 | OPHTHALMIC CONTACT LENS SOLUTIONS CONTAINING FORMS OF VITAMIN B | January 2017 | May 2018 | Allow | 15 | 1 | 0 | No | No |
| 15403412 | INCREASED EFFECTIVENESS OF ALLYLAMINE DRUG COMPOUNDS FOR TOPICAL TREATMENT OF FUNGAL INFECTIONS OF THE SKIN AND SKIN APPENDAGES | January 2017 | June 2019 | Allow | 30 | 1 | 1 | No | No |
| 15399869 | NANOSTRUCTURED ANTIBACTERIAL AND REMINERALIZING DENTAL BONDING AGENTS AND DENTAL BONDING SYSTEMS | January 2017 | November 2017 | Allow | 11 | 0 | 0 | No | No |
| 15376799 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | December 2016 | April 2017 | Allow | 4 | 1 | 0 | No | No |
| 15376851 | METHODS OF PROVIDING ANALGESIA | December 2016 | April 2017 | Allow | 4 | 1 | 0 | No | No |
| 15037513 | COMPOSITIONS, DEVICES AND METHODS FOR CONTROL OF PESTS USING VAPOR ACTIVITY | May 2016 | February 2025 | Allow | 60 | 7 | 1 | Yes | Yes |
| 15134901 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | April 2016 | April 2017 | Allow | 12 | 1 | 0 | No | No |
| 15088534 | SUNSCREEN COMPOSITIONS AND METHODS FOR BOOSTING EFFICACY | April 2016 | June 2018 | Allow | 26 | 3 | 1 | Yes | No |
| 15055749 | OPHTHALMIC CONTACT LENS SOLUTIONS CONTAINING FORMS OF VITAMIN B | February 2016 | October 2016 | Allow | 8 | 1 | 0 | No | No |
| 14950395 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF | November 2015 | February 2016 | Allow | 2 | 0 | 0 | No | No |
| 14770228 | GLUCURONOLACTONE DERIVATIVES AS SELF-TANNING SUBSTANCES | August 2015 | January 2017 | Allow | 17 | 0 | 1 | No | No |
| 14745283 | POLYMER COMPOSITIONS IN BIOMEDICAL APPLICATIONS | June 2015 | December 2019 | Allow | 54 | 5 | 0 | Yes | No |
| 14438493 | Sulfhydryl-Functionalized Polymeric Compositions For Medical Devices | April 2015 | November 2016 | Allow | 19 | 0 | 1 | No | No |
| 14673447 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | March 2015 | August 2015 | Allow | 5 | 1 | 0 | No | No |
| 14672894 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | March 2015 | September 2015 | Allow | 5 | 1 | 0 | No | No |
| 14427853 | HYDROGEL COATED SCAFFOLD | March 2015 | December 2016 | Allow | 21 | 2 | 1 | Yes | No |
| 14635198 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | March 2015 | April 2015 | Allow | 2 | 0 | 0 | No | No |
| 14628261 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | February 2015 | August 2015 | Allow | 6 | 0 | 0 | No | No |
| 14619634 | PARENTERAL COMPOSITIONS OF CELECOXIB | February 2015 | June 2016 | Allow | 16 | 3 | 1 | No | No |
| 14483395 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | September 2014 | January 2015 | Allow | 4 | 1 | 0 | Yes | No |
| 14465027 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | August 2014 | February 2015 | Allow | 5 | 0 | 0 | No | No |
| 14309568 | PESTICIDE COMPOSITIONS EXHIBITING ENHANCED ACTIVITY AND METHODS FOR PREPARING SAME | June 2014 | September 2014 | Allow | 3 | 0 | 0 | No | No |
| 14268264 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | May 2014 | June 2015 | Allow | 13 | 0 | 0 | No | No |
| 14261175 | USE OF UNSATURATED SPHINGOSINE COMPOUNDS AS CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | April 2014 | May 2015 | Allow | 12 | 0 | 0 | No | No |
| 14254183 | STIMULI RESPONSIVE ADHESIVE GEL FOR REMOVAL OF FOREIGN PARTICLES FROM SOFT TISSUE | April 2014 | March 2016 | Allow | 23 | 1 | 1 | No | No |
| 14230396 | ALKYL KETAL ESTERS AS DISPERSANTS AND SLIP AGENTS FOR PARTICULATE SOLIDS, METHODS OF MANUFACTURE, AND USES THEREOF | March 2014 | October 2014 | Allow | 6 | 0 | 0 | No | No |
| 14095509 | Selective Insecticides Based on Anthranilic Acid Diamides and Safeners | December 2013 | May 2014 | Allow | 5 | 1 | 0 | No | No |
| 13942492 | PHARMACEUTICAL CYCLOSPORIN COMPOSITIONS | July 2013 | November 2015 | Allow | 28 | 1 | 1 | Yes | No |
| 13812304 | FUNGICIDAL PYRAZOLES AND THEIR MIXTURES | January 2013 | September 2014 | Allow | 19 | 0 | 0 | No | No |
| 13679605 | OPHTHALMIC CONTACT LENS SOLUTIONS CONTAINING FORMS OF VITAMIN B | November 2012 | December 2015 | Allow | 36 | 3 | 0 | No | No |
| 13623690 | METHOD OF STABILIZING HUMAN EYE TISSUE | September 2012 | April 2015 | Allow | 31 | 1 | 0 | No | No |
| 13405243 | HYDROGEL NANOCOMPOSITE WOUND DRESSING AND A METHOD OF SYNTHESIZING THE SAME | February 2012 | March 2014 | Allow | 25 | 1 | 1 | No | No |
| 13371002 | CHEMICAL COMPOUNDS | February 2012 | June 2013 | Allow | 16 | 1 | 1 | No | No |
| 13270782 | 2-QUINOXALINOL SALEN COMPOUNDS AND USES THEREOF | October 2011 | January 2013 | Allow | 15 | 2 | 1 | No | No |
| 13144686 | FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | September 2011 | December 2013 | Allow | 29 | 1 | 1 | No | No |
| 13186129 | USE OF ANTHRANILAMIDE DERIVATIVES FOR CONTROLLING INSECTS AND SPIDER MITES BY DRENCHING, SOIL MIXING, FURROW TREATMENT, DRIP APPLICATION, SOIL, STEM OR FLOWER INJECTION, IN HYDROPONIC SYSTEMS, BY PLANTING HOLE TREATMENT OR DIP APPLICATION, FLOATING OR SEEDBOX APPLI | July 2011 | November 2013 | Allow | 28 | 1 | 1 | No | No |
| 13002093 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, AND COMPOUND | April 2011 | June 2013 | Allow | 30 | 1 | 1 | No | No |
| 12743353 | Topical Cosmetic Skin Lightening Compositions and Methods of use Thereof | April 2011 | August 2015 | Allow | 60 | 5 | 0 | No | Yes |
| 13007776 | ACIDIC PROCESSES TO PREPARE ANTIMICROBIAL CONTACT LENSES | January 2011 | February 2016 | Allow | 60 | 1 | 0 | No | Yes |
| 12934893 | PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE | December 2010 | November 2014 | Allow | 50 | 3 | 0 | Yes | Yes |
| 12934451 | PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE | December 2010 | June 2014 | Allow | 45 | 2 | 0 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BASQUILL, SEAN M.
With a 42.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BASQUILL, SEAN M works in Art Unit 1614 and has examined 128 patent applications in our dataset. With an allowance rate of 71.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 35 months.
Examiner BASQUILL, SEAN M's allowance rate of 71.9% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by BASQUILL, SEAN M receive 2.18 office actions before reaching final disposition. This places the examiner in the 74% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BASQUILL, SEAN M is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +0.0% benefit to allowance rate for applications examined by BASQUILL, SEAN M. This interview benefit is in the 10% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 17.7% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 31.6% of cases where such amendments are filed. This entry rate is in the 38% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 63.6% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.1% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.